Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants
Crossref DOI link: https://doi.org/10.1007/s41669-017-0042-3
Published Online: 2017-07-17
Published Print: 2018-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Shahabi, Ahva
Peneva, Desi
Incerti, Devin
McLaurin, Kimmie
Stevens, Warren
Funding for this research was provided by:
AstraZeneca
License valid from 2017-07-17